GCM
MAZE

Ghisallo Capital Management’s Maze Therapeutics MAZE Stock Holding History

Ghisallo Capital Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$368K – 266
2025
Q2 		$368K Hold
30,000
– – 0.01% 179
2025
Q1 		$330K Buy
+30,000
New +$361K 0.03% 104

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Ghisallo Capital Management's MAZE Position: Q3 2025 in Review

Ghisallo Capital Management sold out of Maze Therapeutics (MAZE) in Q3 2025, closing a stake of 30,000 shares — an estimated $368K sold.

Ghisallo Capital Management first reported a position in MAZE in Q1 2025 and held it in 2 quarters. The position peaked at $368K in Q2 2025. 94 funds tracked by Wall St. Rank hold MAZE as of Q3 2025.

  • Ghisallo Capital Management reported no remaining Maze Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ghisallo Capital Management sold 30,000 Maze Therapeutics shares in Q3 2025, an estimated $368K.
  • Ghisallo Capital Management first reported a position in Maze Therapeutics in Q1 2025 and held it in 2 quarters.
  • Ghisallo Capital Management's Maze Therapeutics position peaked at $368K in Q2 2025.
  • 94 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2025.

Based on Ghisallo Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.